Grill J, et al. - In this trial, it was shown that addition of bevacizumab (BEV) to radiotherapy plus temozolomide (RT+TMZ) did not improve event-free survival (EFS) in pediatric patients with newly diagnosed high-grade glioma (HGG). The findings of this study were in contrast to the results of previous adult trials.